Giant cell arteritis

International Ophthalmology Clinics

Volumn 47, Issue 4, 2007, Pages 105-119

  Pineles, Stacy L ^a   Arnold, Anthony C ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

BLOOD VESSEL BIOPSY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; ECHOGRAPHY; EXTRAOCULAR MUSCLE; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; ISCHEMIC OPTIC NEUROPATHY; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETINA ARTERY OCCLUSION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BIOPSY; EYE FUNDUS; EYE MOVEMENT DISORDER; ISCHEMIA; OPTIC NERVE; OPTIC NERVE DISEASE; PATHOLOGY; TEMPORAL ARTERY; VASCULARIZATION;

BIOPSY; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIA; OCULAR MOTILITY DISORDERS; OCULOMOTOR MUSCLES; OPTIC NERVE; OPTIC NERVE DISEASES; PROGNOSIS; TEMPORAL ARTERIES;

EID: 38449094575     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e318157fb08     Document Type: Review

References (91)

1. Hutchinson J. On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg (London). 1890;1:323-329.
2. Horton B, Magath TB, Brown GE. An undescribed form of arthritis of the temporal vessels. Proc Mayo Clin. 1932;7:700-701.
3. Jennings G. Arteritis of the temporal vessels. Lancet. 1938;1:424-428.
4. Gilmour J. Giant-cell chronic arteritis. J Pathol. 1941;52:263-277.
5. Machado E, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum. 1988;31:745-749.
6. Bengtsson B, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica, incidences of different clinical presentations and eye complications. Arthritis Rheum. 1981;24:899-904.
7. Pipinos I, Hopp R, Edwards WD, et al. Giant-cell temporal arteritis in a 17-year-old male. J Vasc Surg. 2006;43:1053-1055.
8. Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol. 2005;50:415-428.
9. Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123:192-194.
10. Larsson K, Mellstron D, Nordborg E, et al. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis. 2006;65:529-532.
11. Narvaez J, Bernad B, Diaz Torne C, et al. Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006;33:1293-1298.
12. Kemp A. Monozygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmol. 1977;55:183-190.
13. Wernick C, Duvey M, Bonafede P. Familial giant cell arteritis: report of an HLA-typed sibling pair and review of the literature. Clin Exp Rheumatol. 1994;12:63-66.
14. Calamia K, Moore SB, Elveback LR, et al. HLA-dR locus antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol. 1981;8:993-996.
15. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
16. Morgan A, Robinson JI, Barrett JH, et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther. 2006;8:R109.
17. Boiardi L, Salvarani C, Timms JM, et al. Interleukin-1 cluster and tumor necrosis factor-a gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:675-681.
18. Mattey D, Hajeer AH, Dababneh A, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum. 2000;43:1749-1755.
19. Salvarani C, Casali B, Boiardi L, et al. Intracellular adhesion molecule 1 polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol. 2002;29:502-504.
20. Weyand C, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol. 2000;75:S9-S15.
21. Lie J. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am. 1995;21:883-909.
22. Wilkinson I, Russell RW. Arteries of the head and neck in giant cell arteritis. Arch Neurol. 1972;27:378-391.
23. Gordon L, Goldman M, Sandusky H, et al. Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol. 2004;111:286-296.
24. Gabriel S, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis. Arthritis Rheum. 1999;42:1255-1258.
25. Nordborg C, Nordborg E, Petursdottir V, et al. Search for Varicella zoster virus in giant cell arteritis. Ann Neurol. 1998;44:413-414.
26. Rimeti G, Blasi F, Cosentini R, et al. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an arterial specimen. J Rheumatol. 2001;28:1738-1739.
27. Regan M, Wood BJ, Hsieh YH, et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum. 2002;46:1056-1060.
28. Rodriguez-Pla A, Bosch-Gil JA, Echevarria-Mayo JE, et al. No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis. J Clin Virol. 2004;31:11-15.
29. Chess J, Albert DM, Bhan AK, et al. Serologic and immunopathologic findings in temporal arteritis. Am J Ophthalmol. 1983;96:283-289.
30. Espinoza L, Jara JL, Silveira LH, et al. Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: association with severe vascular complications. Am J Med. 1991;90:474-478.
31. Carroll S, Gaskin BJ, Danesh-Meyer HV. Giant cell arteritis. Clin Exp Ophthalmol. 2006;34:159-173.
32. Liu G, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis of vision. Ophthalmology. 1994;101:1779-1185.
33. Hayreh S, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509-520.
34. Arnold A. Ischemic optic neuropathy. In: Miller N, Newman NJ, eds. Walsh and Hoyt's Clinical Neuro-Ophthalmology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
35. Slavin M, Barondes MJ. Visual loss caused by choroidal ischemia preceding anterior ischemic optic neuropathy in giant cell arteritis. Am J Ophthalmol. 1994;117:81-86.
36. Sadda S, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol. 2001;132:743-750.
37. Huston K, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978;88:162-167.
38. Hollenhorst R, Brown JR, Wagener HP, et al. Neurologic aspects of temporal arteritis. Neurology. 1960;10:490-498.
39. Shah A, Paul-Oddoye AB, Madill SA, et al. Horner's syndrome associated with giant cell arteritis. Eye. 2007;21:130-131.
40. McKillop E, Tejawani D, Weir C, et al. Anterior segment ischaemia with giant cell arteritis. Can J Ophthalmol. 2006;41:201-203.
41. Calcagni A, Claes CA, Maheshwari M, et al. Hypotony as a presentation of giant cell arteritis. Eye. 2007;21:123-124.
42. Caselli R, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988;38:352-359.
43. Manetas S, Moutzouris DA, Falagas ME. Scalp necrosis: a rare complication of temporal arteritis. Clin Rheumatol. 2006. [Epub ahead of print].
44. Hayreh S, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol. 1998;125:521-526.
45. Smetana G, Shmerling RH. Does this patient have temporal arteritis. JAMA. 2002;287:92-101.
46. Niederkohr R, Levin LA. Management of the patient with suspected temporal arteritis. A decision-analytic approach. Ophthalmology. 2005;112:744-756.
47. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. BMJ. 1983;286:266.
48. Hayreh S, Podhajsky P, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123:285-296.
49. Zweegman S, Makkink B, Stehouwer CD. Giant cell arteritis with normal erythrocyte sedimentation rate: case report and review of the literature. Neth J Med. 1993;42:128-131.
50. Deodhar S. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56:126-130.
51. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113:1842-1845.
52. Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2002;109:1267-1271.
53. Liozon E, Hermann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.
54. Achkar A, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis. Ann Intern Med. 1994;120:987-992.
55. Allison M, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis. 1984;1984:416-417.
56. Font R, Prabhakran VC. Histologic parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases. Br J Ophthalmol. 2007;91:204-209.
57. Weyand C, Bartley GB. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol. 1997;123:392-395.
58. Cohen D, Smith TR. Skip areas in temporal arteritis: myth versus fact. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:772-783.
59. Danesh-Meyer H, Savino PJ, Eagle RC, et al. Low diagnostic yield with second biopsies in suspected giant cell arteritis. J Neuro-ophthalmol. 2000;20:213-215.
60. Pless M, Rizzo JF, Lamkin JC, et al. Concordance of bilateral temporal artery biopsy in giant cell arteritis. J Neuro-ophthalmol. 2000;20:216-218.
61. Boyev L, Miller NR, Gree WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128:211-215.
62. Hayreh S. Anterior ischaemic optic neuropathy II. Fundus on ophthalmoscopy and fluorescein angiography. Br J Ophthalmol. 1974;58:964-980.
63. Arnold A, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;117:222-230.
64. Karassa F, Matsaga MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142:359-369.
65. Karahaliou M, Vaiopoulos G, Papaspyrou S, et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther. 2006;8:R116.
66. Bley T, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteries: imaging of the wall of the superficial temporal artery. Am J Roentgenol. 2005;184:283-287.
67. Vianna R, Mansour M, Ozdal PC, et al. The role of ultrasound biomicroscopy in predicting the result of temporal artery biopsy in temporal arteritis patients: a preliminary study. Eur J Ophthalmol. 2005;15:655-659.
68. Lee A, Eggenberger ER, Kaufman DI, et al. Optic nerve enhancement on magnetic resonance imaging in arteritic ischemic optic neuropathy. J Neuroophthalmol. 1999;19:235-237.
69. Hayreh S, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology. 2001;108:1586-1594.
70. Hayreh S, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003;217:239-259.
71. Hayreh S, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of the literature. Acta Ophthalmol Scand. 2002;80:355-367.
72. Hayball P, Cosh DG, Ahern MJ, et al. High-dose oral methylprednisolone in patients with rheumatoid arthritis: pharmokinetics and clinical response. Eur J Clin Pharmacol. 1992;42:85-88.
73. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol. 2000;27:1484-1491.
74. Hayreh S, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110:1204-1215.
75. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/ recurrence in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum. 2005;53:33-38.
76. Provon A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and treatment outcomes. Arthritis Rheum. 2003;49:703-708.
77. Kyle V, Hazelman BL. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ. 1990;300:344-345.
78. Blumberg S, Giansiracusa DF, Docken WP, et al. Recurrence of temporal arteritis. Clinical recurrence nine years after initial illness. JAMA. 1980;244:1713.
79. Caporali R, Cimmino MA, Ferraccioli GF, et al. Prednisone plus methotrexate for polymyalgia rheumatica. Ann Intern Med. 2004;141:495-501.
80. Jover J, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisolone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-114.
81. Hoffman G, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-1318.
82. Spiera R, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495-501.
83. Airo P, Antoniolo CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology. 2002;41:347-349.
84. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis. 1986;45:136-138.
85. De Vita S, Tavoni A, Jeracitano G, et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med. 1992;232:373-375.
86. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications of giant cell arteritis. Arthritis Rheum. 2004;50:1332-1337.
87. Danesh-Meyer H, Savino PJ, Gamble GD. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005;112:1098-1103.
88. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110:539-542.
89. Aiello P, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550-555.
90. Uddhammar A, Eriksson AL, Nystrom L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29:737-742.
91. Matteson E, Gold KN, Bloch DA, et al. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 1996;100:193-196.